Clinical Trials Logo

Ulcerated Melanomas clinical trials

View clinical trials related to Ulcerated Melanomas.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT01502696 Active, not recruiting - Ulcerated Melanomas Clinical Trials

Adjuvant PEG Intron in Ulcerated Melanoma

Start date: October 2012
Phase: Phase 3
Study type: Interventional

Patients with an ulcerated melanoma with Breslow >1 mm, N0M0 have a significantly higher risk for relapse than patients with a non-ulcerated primary and about a 40-50% chance of developing stage IV disease to which they will almost invariably succumb. In stage I and II patients with an ulcerated primary who have been sentinel node (SN-staged) and found to be SN-negative there is still a 25-30% relapse risk. The purpose of this study is to evaluate the effectiveness and safety when treated with PEG IFN alfa-2b for 2 years as compared to observation (no treatment), administered after adequate surgery has been performed for ulcerated primary cutaneous melanomas.